ARID1A and neoplasm: Goswami et al. further analyzed two separate cohorts of patients in CheckMate-275 and in IMvigor210 who received nivolumab and atezolizumab, respectively, for progressive disease for AT-rich interactive domain-containing protein 1A (ARID1A) mutations and immune cytokine CXCL13 gene expression in baseline tumor tissues [28].